INmune Bio IncINMB
Price$1.93

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $50K+257.1% YoYTTM through 30 Jun 2026
Net Income -$45.9MTTM through 30 Jun 2026
Free Cash Flow -$16MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-94,766.0%
Net Margin-91,866.0%

Returns

-212.0%ROE
-161.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.55x
Net Debt-$21.4Mnet cash position
Cash & Equivalents$24.8M

Quality Metrics

Altman Z-Score-10.72
Piotroski F-Score2 / 9
FCF Margin-32,006.0%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'18'20'21'22'23'24'25
FY2025: $50K
Diluted EPS-$0.62TTM
'21'22'23'24'25
FY2025: $-1.86

Dividend

No dividend

Capital Allocation

R&D Spend$16.7M
Capex Intensity2,084.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.